+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 576 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.

Age: 18Years +All GendersPhase 2Phase 3
88 locations
P

Actively Recruiting

Researchers are studying patients with soft tissue sarcoma of the extremity, trunk, or retroperitoneum to evaluate a shorter, five-day course of preoperative radiation therapy. This approach is being compared to the standard preoperative radiation given over 25 days to assess safety and effectiveness. The study is a Phase 2 trial sponsored by Stanford University focusing on treatment for this type of cancer. Participants will receive external beam radiotherapy delivering a total dose of 30 Gy divided into five equal daily fractions of 6 Gy each over 5 to 10 business days before surgery. This abbreviated radiation schedule aims to reduce the treatment duration while still targeting the tumor and any areas where microscopic disease might exist. During the study, participants will be monitored for post-operative complications up to 120 days after surgery. Researchers will also evaluate the rates of local cancer recurrence at 2 and 5 years following surgical removal. The study includes assessments of health status, and participants must attend scheduled visits for treatment and follow-up as part of their involvement, which continues until at least the primary outcome measurement is completed.

Age: 18Years +All GendersPhase 2
1 location
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are studying ways to prevent cytomegalovirus CMV infection in children and adolescents who have received a kidney transplant and weigh less than 40 kilograms. This trial focuses on understanding how the drug letermovir behaves in the body over time and assessing its safety and tolerance in this young population. The study is a phase 1, open-label, single-arm trial sponsored by Merck Sharp & Dohme LLC. Participants who are between 4 and 52 weeks post-kidney transplant will receive oral letermovir, either as tablets or pellets, or via gastrostomy or nasogastric tube pellets only for 7 consecutive days. The study uses weight-banded dosing to tailor the treatment to each child or adolescents weight. During the study, participants will be closely monitored with blood sampling to measure letermovir levels over a 24-hour period on Day 7. Researchers will also track any adverse events for up to 21 days and note if any participant stops the treatment due to side effects within 7 days. The total study duration for each participant includes the treatment period and safety monitoring, extending until the primary outcome data is collected.

Age: 0 - 17YearsAll GendersPhase 1
22 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of two PTSD treatments, Cognitive Processing Therapy CPT and STAIR Narrative Therapy SNT, among adults who identify as part of the LGBTQIA community. The study aims to find out which treatment better reduces PTSD symptoms, improves quality of life, and lessens depression. It also explores how stress from stigma, discrimination, and drug or alcohol use may affect treatment outcomes, and whether these treatments work differently for various groups within the LGBTQIA population. Participants will be randomly assigned to receive either CPT, which involves about 12 sessions focusing on changing beliefs and processing emotions related to trauma, or SNT, a longer therapy with about 16 sessions including coping skills for emotional regulation and a trauma-focused narrative component. Treatments are delivered either in person or via videoconferencing. The study compares these two therapies to understand which is more effective for LGBTQIA adults with PTSD. During the study, participants will complete assessments at the start and at 3, 6, and 12 months to measure changes in PTSD symptoms, depression, quality of life, and satisfaction with therapy. Researchers will also track treatment completion rates. The total participation time covers these assessments and treatment sessions, with monitoring to understand how well participants respond and adhere to the therapies.

Age: 18Years +All GendersPhase Not Applicable
2 locations
O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
E

Actively Recruiting

Researchers are evaluating the safety and potential benefits of the Eclipse XL1 System in both children and adults who have short bowel syndrome, a condition where part of the small intestine is missing or has been removed. This single-group, open-label clinical study includes participants aged from 3 months to 65 years old and is conducted across multiple sites in the United States to better understand how this device might help with intestinal growth. The study involves placing the Eclipse XL1 device inside the intestine during either a standalone surgery or an already planned procedure. Participants may receive up to two devices simultaneously or undergo multiple procedures if needed. The device is secured inside the intestine and marked with metal clips to monitor its position. Researchers will track how the device affects intestinal lengthening and nutritional status over time, and the device will be observed through imaging until it is removed or naturally passes out. Participants will be monitored while the device is in place and followed up at 3 and 6 months after the device is removed or passes naturally. During the study, their nutrition, weight, and stool will be assessed, and radiographic exams will confirm device placement and safety. Depending on their health, subjects may stay in the hospital or be discharged while participating. The total study duration allows for careful evaluation of device-related adverse events and improvements in intestinal health.

Age: 3Months - 65YearsAll GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.

Age: 18Years +All GendersPhase 1
45 locations
E

Actively Recruiting

Researchers are studying the safety and effectiveness of a gene transfer therapy called delandistrogene moxeparvovec in males with Duchenne Muscular Dystrophy DMD, including those who are non-ambulatory. This open-label study is focused on evaluating how well the gene therapy expresses dystrophin protein in the muscles and monitoring any side effects over a period of up to 156 weeks. The study is sponsored by Sarepta Therapeutics, Inc. and targets participants aged 2 years and older with a confirmed diagnosis of DMD. Participants will receive a single intravenous infusion of delandistrogene moxeparvovec on Day 1. The study involves different cohorts, with Cohort 8 currently enrolling non-ambulatory participants who meet specific motor function and steroid use criteria. The therapy aims to deliver the gene using a systemic approach, and participants will be monitored closely for safety and gene expression through various laboratory and clinical assessments. Throughout the study, participants will undergo regular evaluations including laboratory tests, muscle biopsies to measure dystrophin protein levels, and monitoring for adverse events such as liver injury or immune responses. Researchers will track antibody levels to the viral vector used in the gene therapy and assess the presence of the gene product at specific time points, especially at 12 weeks post-infusion. The total duration of participation may last up to 156 weeks, with ongoing safety and efficacy checks throughout this period.

Age: 2Years +MALEPhase 1
12 locations
L

Actively Recruiting

This observational study focuses on individuals with Recessive Dystrophic Epidermolysis Bullosa RDEB who were treated with prademagene zamikeracel pz-cel, a gene therapy made from the participants own skin cells and applied surgically to treat wounds. The study aims to evaluate the long-term safety of pz-cel, the durability of wound healing, and the occurrence of any malignancies after treatment in the post-marketing setting. Participants who have received pz-cel treatment will be followed for up to 15 years after their treatment. Assessments will primarily be collected remotely on an annual basis, but if the participants healthcare provider deems it necessary after the first year, some data may be collected during in-person visits. Annual evaluations will include reviewing adverse events, serious adverse events, hospitalizations, evidence of malignancies, potential retroviral infections, wound healing status based on caregiver reports, and any changes in medications or procedures. Throughout the study, participants will provide data annually for up to 15 years post-treatment. Researchers will monitor the number and incidence of treatment-related malignancies, serious adverse events including wound-specific events, and any positive retroviral infection test results. This long-term follow-up aims to understand the safety profile and wound healing durability of pz-cel, with participants contributing data primarily through remote means and occasional in-person assessments as needed.

All AgesAll Genders
4 locations

1-10 of 576

1